ReviewNature reviews. Microbiology2025
Global health perspectives on antibacterial drug discovery and the preclinical pipeline.
Review in Nature reviews. Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- From lipophilicity windows to decision-grade antibacterial design: the next translational step for coumarin amphiphiles.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Article
- Molecular action of NZ2114, a superior plectasin derivative.npj antimicrobials and resistance · 2026Article
- Interfacial Chemistry-Tailored Silica&Metal-Based Heterostructures: from Rational Design to Antibacterial Applications.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Diversity and antimicrobial products of culturable coral-associated actinomycetes in Hainan.Antonie van Leeuwenhoek · 2026Article
- Antimicrobial activity ofmicroPublication biology · 2026Article
- Electroresponsive Strategies to Combat Bacterial Infections.Research (Washington, D.C.) · 2026Review
- The WHO priority list of antibiotic-resistant bacteria: challenges and opportunities for next-generation antimicrobial development.Frontiers in pharmacology · 2026Review
- A review of research progress on periplasmic adaptor proteins in bacterial tripartite pumps.Frontiers in microbiology · 2026Review
- Combating Bacterial Infection with Metabolism-Regulating Nanomaterials.International journal of nanomedicine · 2026Review
- Cross-species transmission ofFrontiers in cellular and infection microbiology · 2026Review
- Special Issue: Polymers, Polymer Blends, and Polymeric Drug Release Systems with Antiviral or Antibacterial Effect-2nd Edition.International journal of molecular sciences · 2025Article
- New approach to overcoming antimicrobial resistance of by combining Guanghuoxiang () and Penicillin G Sodium treatments.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Immune transcriptomic differences in paediatric patients with SARS-CoV-2 compared to other lower respiratory tract infections.bioRxiv : the preprint server for biology · 2025Article
- A unique inhibitor conformation selectively targets the DNA polymerase PolC of Gram-positive priority pathogens.Nature communications · 2025Article
- Identification of novelRSC medicinal chemistry · 2025Article
- Production of the Antimicrobial Roseoflavin With Genetically Engineered Corynebacterium glutamicum.Microbial biotechnology · 2025Article
- Pentamidine inhibition of streptopain attenuatesMicrobiology spectrum · 2025Article
- Efflux-Mediated Resistance inAntibiotics (Basel, Switzerland) · 2025Review
- Biomaterials mediated 3R (remove-remodel-repair) strategy: holistic management of Helicobacter pylori infection.Journal of nanobiotechnology · 2025Review
- Challenges of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibacterial resistance is a global challenge that requires a coordinated international response. The current clinical pipeline largely consists of derivatives of established antibiotic classes, whereas the discovery and preclinical pipeline is diverse and innovative including new direct-acting agents with no cross-resistance with existing antibiotics. These novel compounds target pathways such as lipoprotein synthesis, lipopolysaccharide biosynthesis and transport, outer membrane assembly, peptidoglycan biosynthesis, fatty acid biosynthesis and isoprenoid biosynthesis. If these agents can be developed into safe, effective and affordable drugs, they could address a broad range of infections worldwide, benefiting large patient populations without geographical limitations. However, strategies such as indirect-acting or pathogen-specific treatments are likely to benefit small patient groups, primarily in high-income countries that have advanced health-care systems and diagnostic infrastructure. Although encouraging, the discovery and preclinical pipeline remains insufficiently robust to offset the high attrition rates typical of early-stage drug innovation and to meet global health needs.
Indexed as
Identifiers
40148602What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.